CagriSema misses non-inferiority against tirzepatide at 84 weeks
Novo Nordisk shares closed down 16.5% in Copenhagen at 251 Danish kroner, their lowest level since June 2021, while Eli Lilly gained 4.9%.
MH
By Maren Holt · Senior Reporter, GLP-1
Feb 23 03:00 ETSource: cnbc.com
The wire
- 01Novo Nordisk said patients on 2.4 mg CagriSema lost 23% of body weight at 84 weeks versus 25.5% on 15 mg tirzepatide, missing the trial's non-inferiority primary endpoint.
- 02CagriSema, a semaglutide plus cagrilintide combination, is already filed with the FDA with a decision expected by late 2026, shaping what prescribers can expect next in the incretin class.
- 03The trial was open-label, which Novo's chief scientific officer Martin Holst Lange said can bias results toward a well-known marketed product; Novo says it is exploring higher-dose combination trials.
From the source
Read at cnbc.comNovo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial
Novo Nordisk 's stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its key goal of showing that it wasn't inferior to Eli Lilly' s rival drug, in the latest blow to the Danish drugmaker, whose stock is trading at a multi-year low after a series of disappointing announcements .
